# Alithea Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alithea-genomics

- Industry: Biotechnology
- Headquarters: Epalinges, Switzerland
- Website: www.alitheagenomics.com
- Total disclosed funding: $8.1M
- Latest round: Seed (Mar 4, 2026)
- Investors on record: 3

## About

Based in Epalinges, Switzerland, and founded in 2020 by Bart Deplancke, Daniel Alpern, and Riccardo Dainese, Alithea Genomics operates as a biopharma industry background in bioengineering, molecular biology, genomics, and lab operations and also provides transcriptomics solutions for research and biomarker discovery. As of September 2023, Riccardo Dainese is the Chief Executive Officer (CEO) of the company. In March 2026, Alithea Genomics SA raised CHF 3 million in seed funding led by Genku Ventures, with participation from Zurcher Kantonalbank and Novalis Biotech.

Alithea Genomics SA is a business that has created a low-cost transcriptomics system to help in biomedical advances. The company provides a transcriptomics platform that uses mercurius technology to reduce the costs of RNA sequencing while significantly boosting sample analysis capacity. This gives pharmaceutical companies the ability to do substantial biological research.

The company plans to utilize the March 2026 funding to expand MERCURIUS™ DRUG-seq kit commercialization, develop new technologies, and grow transcriptomic data for AI and machine learning.

## Funding rounds

- Seed, Mar 4, 2026, $3.9M — Zurcher Kantonalbank, Novalis Biotech
- Seed, Mar 14, 2024, $3.2M — TechU Ventures, Novalis Biotech
- Seed, May 24, 2022, $1M — Novalis Biotech

## Investors

- Novalis Biotech (https://capitalatlas.ai/funds/novalis-biotech) — Seed
- TechU Ventures (https://capitalatlas.ai/funds/techu-ventures) — Seed
- Zurcher Kantonalbank — Seed